History was made at the United Nations today, when the UN’s Commission for Narcotic Drugs narrowly voted to remove cannabis from a list of drugs previously judged to have little-to-no medicinal benefits. Vice reports that in a 27 to 25 vote victory, the US and UN cast the final two deciding votes to now officially remove cannabis from Schedule IV of the 1961 Single Convention on Narcotic Drugs — potentially opening up the plant to increased medicinal access throughout Europe, along with additional scientific research.
Translation: Your stoner cousin was right — weed is medicine. And now we’re a significant step closer to being able to get the type of research funded that will tell us precisely how it’s best used. The legal status of cannabis has always been a major hurdle when it comes to funding meaningful scientific research studying the long term medicinal benefits of THC, so the United Nations recognizing the medical value of weed remedies some of the unjust prejudice that has been unfairly placed on the plant, despite the historical use of cannabis as a medicine that stretches back to ancient Greece and Egypt. And, as we’ve covered before, medicinal recognition leads to medical legalization which always, always leads to eventual recreational legalization. So this move is a big win for weed worldwide.
To date, 50 countries worldwide have adopted medicinal cannabis programs, and the plant is now fully legal in Canada, Uruguay, and 15 US states. Mexico and Luxembourg are also expected to join the countries that have legalized weed in the near future, with the vote passing Mexico’s senate just days ago.
The medical marijuana market is poised to grow by USD 22.33 billion during 2020-2024 progressing at a CAGR of over 24% during the forecast period.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005680/en/
Technavio has announced its latest market research report titled Global Medical Marijuana Market 2020-2024 (Graphic: Business Wire)
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Download Free Sample Report on COVID-19 Recovery Analysis
The report on the medical marijuana market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing production of medical marijuana.
The medical marijuana market analysis includes application and geography landscape. This study identifies the increase in funding for research and production of medical marijuana as one of the prime reasons driving the medical marijuana market growth during the next few years.
This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters
The Medical Marijuana Market covers the following areas:
Medical Marijuana Market Sizing
Medical Marijuana Market Forecast
Medical Marijuana Market Analysis
Aurora Cannabis Inc.
Cannabis Sativa, Inc.
Canopy Growth Corp.
Cronos Group Inc.
GW Pharmaceuticals Plc
Medical Marijuana, Inc.
United Cannabis Corp.
Vivo Cannabis, Inc.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY APPLICATION
Market segmentation by application
Comparison by application
Chronic pain – Market size and forecast 2019-2024
Nausea – Market size and forecast 2019-2024
Others – Market size and forecast 2019-2024
Market opportunity by application
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
North America – Market size and forecast 2019-2024
Europe – Market size and forecast 2019-2024
APAC – Market size and forecast 2019-2024
South America – Market size and forecast 2019-2024
MEA – Market size and forecast 2019-2024
Key leading countries
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
Increasing number of awareness campaigns
Launch of medical marijuana education programs
Increase in funding for research and production of medical marijuana
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
PART 15: EXPLORE TECHNAVIO
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all
EDITOR’S NOTE:NJ Cannabis Insider produces exclusive weekly content and monthly events geared toward those interested in the marijuana and hemp industries. To subscribe, visit njcannabisinsider.biz.
Not long after state Sen. Nick Scutari claimed on Tuesday legislators and regulators may “be able to flip the switch and people might be able to get marijuana, legally, right after the vote,” the head of the state medical cannabis program doused that pipe dream with a bucket of cold water.
“(Some dispensaries) literally do not even have the space to accommodate the level of demand that personal-use sales would bring,” said Jeff Brown, who helms the Department of Health’s Medicinal Marijuana Program. “I could say unequivocally that opening up sales even a few months after the election would be a disaster and would really hurt access for patients who need this as medicine. My number one priority is to ensure that the patients have access — that’s going to be our priority first and foremost.”
Since the passage of Jake Honig’s Law, the medical program continues to grow in terms of patients and demand — about 7,000 patients per month on average and nearly 95,000 patients enrolled in total — but the program continues to face supply challenges for just the current patient population due to the small number of operational cultivators and canopy space.
Scutari, in his comments during an interview with NJ Cannabis Insider streamed live on NJ.com’s Facebook page Tuesday, that “(the) currently operating medical cannabis dispensaries would have an opportunity to sell to the general public for people over 21, if they can certify that they have enough product to satisfy their patients that they’re already treating.”
Brown, who also participated in a closed portion of the webinar, tamped down the senator’s suggestion at the time. He said he wants to keep an open dialogue with legislators and make the program’s priorities clear to medical patients and Garden State citizens as a whole.
“Inventories at alternative treatment centers are increasing, too, but it’s uneven,” he said. “We have some that are expanding capacity and then we have others that are simply maintaining and have really no room to expand cultivation in their current footprints.”
For the past six months, Brown said, the medical cannabis program has averaged about only 2,100 pounds in sales per month, rising to nearly 2,500 in September with a similar trend in October. Based on an average of the patient population, patients typically only buy a half-ounce each month, he said.
As of this past Friday, Brown said, there were about 10,000 pounds of medical cannabis in the market — about evenly split between flower and extracts, though flower tends to have higher sales. That means there’s enough medical cannabis to last about four months, given current sales trends and more limited choices for patients.
Part of the challenges dispensaries face, Brown said, is the small indoor canopy. There’s a dozen cultivators in New Jersey, but the average dispensary only has a canopy of
FRIDAY, Oct. 30, 2020 (HealthDay News) — Teenage boys who see ads for pot are more likely than girls to link marijuana with better sex, a new study suggests.
The reason? Many boys think people who use pot are less inhibited and enjoy sex more, which leads them to want to try marijuana in the future. Girls and young women, however, are less likely to use pot based on messages that connect it to sex, the researchers found.
“The messages adolescents and young adults are seeing are part of what is having impact, the type of appeal and the content, not just the fact that young people are seeing these messages on social media,” said lead author Jessica Fitts Willoughby, an associate professor with the Murrow College of Communication at Washington State University. “Messages matter.”
Beyond the connection between marijuana and sex, advertising and social media that portrays marijuana in any positive light affects teens and young adults, Willoughby added.
Parents need to talk with their kids about having a more critical attitude toward marijuana messages, said co-author Stacey Hust, an associate professor at Murrow.
“The next step is to identify how advertisements affect people as it relates to sex-related marijuana expectancies, as well as the intent for use before and after sex,” Hust said in a university news release.
For the study, the researchers surveyed 350 teens aged 15 to 17 and nearly 1,000 college-aged adults. Regardless of age or sex, researchers found that those who saw more pro-marijuana content on social media intended to use pot in the future.
These findings suggest that regulations of the content of marijuana advertisements, not just where marijuana advertisements are placed, may be needed.
Females and college-aged men did not have the same expectations of pot and its effects on sex as younger boys. The researchers don’t know why older males weren’t influenced in the same way, but one possibility is that college men have more sexual experience to draw on as a means of forming their opinion of sex and marijuana.
The findings were published recently in the Journal of Sex Research.
SOURCE: Washington State University, news release, Oct. 28, 2020
His team reported, “Although marijuana is smoked with fewer puffs, larger puff volumes and longer breath holds may yield greater delivery of inhaled elements.” In other words, when compared to tobacco smoking, exposure to chemicals damaging to the heart and lungs may be even greater from smoking marijuana.
Dr. Vaduganathan said he was especially concerned about the increasing number of heart attacks among marijuana users younger than 50. In a registry of cases created by his colleagues, in young patients suffering a first heart attack, “marijuana smoking was identified as one factor that was more common among them.” The registry revealed that, even when tobacco use was taken into account, marijuana use was associated with twice the hazard of death among those under age 50 who suffered their first heart attack.
Other medical reports have suggested possible reasons. A research team headed by Dr. Carl J. Lavie of the John Ochsner Heart and Vascular Institute in New Orleans, writing in the journal Missouri Medicine, cited case reports of inflammation and clots in the arteries and spasms of the coronary arteries in young adults who smoke marijuana.
Another damaging effect that has been linked to marijuana is disruption of the heart’s electrical system, causing abnormal heart rhythms like atrial fibrillation that can result in a stroke. In one survey of marijuana smokers, the risk of stroke was increased more than threefold.
These various findings suggest that a person need not have underlying coronary artery disease to experience cardiovascular dysfunction resulting from the use of marijuana. There are receptors for cannabinoids, the active ingredients in marijuana, on heart muscle cells and blood platelets that are involved in precipitating heart attacks.
Cannabinoids can also interfere with the beneficial effects of various cardiovascular medications, including statins, warfarin, antiarrhythmia drugs, beta-blockers and calcium-channel blockers, the Boston team noted.
The researchers found that in an analysis of 36 studies among people who suffered heart attacks, the top three triggers were use of cocaine, eating a heavy meal and smoking marijuana. And 28 of 33 systematically analyzed studies linked marijuana use to an increased risk of what are called acute coronary syndromes — a reduction of blood flow to the heart that can cause crushing chest pain, shortness of breath or a heart attack.
ST. LOUIS — Missouri’s first licensed marijuana dispensaries opened this weekend in the St. Louis area with long lines.
The two dispensaries run by N’Bliss opened Saturday in Ellisville and Manchester. Another dispensary is expected to open Monday in the Kansas City area nearly two years after Missouri voters approved a constitutional amendment to allow the sale of medical marijuana.
To buy the drug, people need approval from a doctor and a state medical marijuana card. Prices are expected to be high initially because the supply is limited in the state at this stage. N’Bliss was charging $125 for an eighth of an ounce of marijuana when it opened Saturday.
Kim Haller said she stood in line Saturday because she has long been frustrated with the high cost of medications and injections she uses to treat her multiple sclerosis. Recently, Haller said she had been buying marijuana from a licensed caregiver.
“It helps with my spasticity, which means my muscles don’t move like I like them to, and sleep,” Haller, 54, of St. Peters, said of the marijuana treatment.
In the Kansas City area, Brenda Dougherty said she hopes to be one of Fresh Green’s first customers when it opens this week in Lee’s Summit. The 57-year-old from Warrensburg said she believes marijuana will help relieve her chronic pain condition.
“I don’t want to take any more pills,” she said. “I know this will help. To be quite honest, I have tried it and, yes, it does help.”
The Missouri Department of Health and Human Services expects most of the state’s 192 approved dispensaries to be open by the end of the year.
“Missouri patients have always been our North Star as we work to implement the state’s medical marijuana program,” Dr. Randall Williams, department director, said in a news release. “We greatly appreciate how hard everyone has worked so that patients can begin accessing a safe and well-regulated program.”